CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2022-11-16
Cited: 0
Clicked: 1287
Citations: Bibtex RefMan EndNote GB/T7714
Xiaoyan TANG, Dezheng CHEN, Ling ZHANG, Ping FU, Yanxia CHEN, Zhou XIAO, Xiangcheng XIAO, Weisheng PENG, Li CHENG, Yanmin ZHANG, Hongbo LI, Kehui LI, Bizhen GOU, Xin WU, Qian YU, Lijun JIAN, Zaizhi ZHU, Yu WEN, Cheng LIU, Hen XUE, Hongyu ZHANG, Xin HE, Bin YAN, Liping ZHONG, Bin HUANG, Mingying MAO. Application of regional citrate anticoagulation in patients at high risk of bleeding during intermittent hemodialysis: a prospective multicenter randomized controlled trial[J]. Journal of Zhejiang University Science B, 2022, 23(11): 931-942.
@article{title="Application of regional citrate anticoagulation in patients at high risk of bleeding during intermittent hemodialysis: a prospective multicenter randomized controlled trial",
author="Xiaoyan TANG, Dezheng CHEN, Ling ZHANG, Ping FU, Yanxia CHEN, Zhou XIAO, Xiangcheng XIAO, Weisheng PENG, Li CHENG, Yanmin ZHANG, Hongbo LI, Kehui LI, Bizhen GOU, Xin WU, Qian YU, Lijun JIAN, Zaizhi ZHU, Yu WEN, Cheng LIU, Hen XUE, Hongyu ZHANG, Xin HE, Bin YAN, Liping ZHONG, Bin HUANG, Mingying MAO",
journal="Journal of Zhejiang University Science B",
volume="23",
number="11",
pages="931-942",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2200082"
}
%0 Journal Article
%T Application of regional citrate anticoagulation in patients at high risk of bleeding during intermittent hemodialysis: a prospective multicenter randomized controlled trial
%A Xiaoyan TANG
%A Dezheng CHEN
%A Ling ZHANG
%A Ping FU
%A Yanxia CHEN
%A Zhou XIAO
%A Xiangcheng XIAO
%A Weisheng PENG
%A Li CHENG
%A Yanmin ZHANG
%A Hongbo LI
%A Kehui LI
%A Bizhen GOU
%A Xin WU
%A Qian YU
%A Lijun JIAN
%A Zaizhi ZHU
%A Yu WEN
%A Cheng LIU
%A Hen XUE
%A Hongyu ZHANG
%A Xin HE
%A Bin YAN
%A Liping ZHONG
%A Bin HUANG
%A Mingying MAO
%J Journal of Zhejiang University SCIENCE B
%V 23
%N 11
%P 931-942
%@ 1673-1581
%D 2022
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2200082
TY - JOUR
T1 - Application of regional citrate anticoagulation in patients at high risk of bleeding during intermittent hemodialysis: a prospective multicenter randomized controlled trial
A1 - Xiaoyan TANG
A1 - Dezheng CHEN
A1 - Ling ZHANG
A1 - Ping FU
A1 - Yanxia CHEN
A1 - Zhou XIAO
A1 - Xiangcheng XIAO
A1 - Weisheng PENG
A1 - Li CHENG
A1 - Yanmin ZHANG
A1 - Hongbo LI
A1 - Kehui LI
A1 - Bizhen GOU
A1 - Xin WU
A1 - Qian YU
A1 - Lijun JIAN
A1 - Zaizhi ZHU
A1 - Yu WEN
A1 - Cheng LIU
A1 - Hen XUE
A1 - Hongyu ZHANG
A1 - Xin HE
A1 - Bin YAN
A1 - Liping ZHONG
A1 - Bin HUANG
A1 - Mingying MAO
J0 - Journal of Zhejiang University Science B
VL - 23
IS - 11
SP - 931
EP - 942
%@ 1673-1581
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2200082
Abstract: ObjectiveSafe and effective anticoagulation is essential for hemodialysis patients who are at high risk of bleeding. The purpose of this trial is to evaluate the effectiveness and safety of two-stage anticoagulation%29&ck%5B%5D=abstract&ck%5B%5D=keyword'>regional citrate anticoagulation (RCA) combined with sequential anticoagulation and standard calcium-containing dialysate in intermittent hemodialysis (IHD) treatment.
MethodsPatients at high risk of bleeding who underwent IHD from September 2019 to May 2021 were prospectively enrolled in 13 blood purification centers of nephrology departments, and were randomly divided into RCA group and saline flushing group. In the RCA group, 0.04 g/mL sodium citrate was infused from the start of the dialysis line during blood draining and at the venous expansion chamber. The sodium citrate was stopped after 3 h of dialysis, which was changed to sequential dialysis without anticoagulant. The hazard ratios for coagulation were according to baseline.
ResultsA total of 159 patients and 208 sessions were enrolled, including RCA group (80 patients, 110 sessions) and saline flushing group (79 patients, 98 sessions). The incidence of severe coagulation events of extracorporeal circulation in the RCA group was significantly lower than that in the saline flushing group (3.64% vs. 20.41%, P<0.001). The survival time of the filter pipeline in the RCA group was significantly longer than that in the saline flushing group ((238.34±9.33) min vs. (221.73±34.10) min, P<0.001). The urea clearance index (Kt/V) in the RCA group was similar to that in the saline flushing group with no statistically significant difference (1.12±0.34 vs. 1.08±0.34, P=0.41).
ConclusionsCompared with saline flushing, the two-stage RCA combined with a sequential anticoagulation strategy significantly reduced extracorporeal circulation clotting events and prolonged the dialysis time without serious adverse events.
[1]ButurovicJ, GubensekJ, CerneD, et al., 2008. Standard citrate versus sequential citrate/anticoagulant-free anticoagulation during hemodialysis: a randomized trial. Artif Organs, 32(1):77-81.
[2]Buturovic-PonikvarJ, CerneS, GubensekJ, et al., 2008. Regional citrate anticoagulation for hemodialysis: calcium-free vs. calcium containing dialysate—a randomized trial. Int J Artif Organs, 31(5):418-424.
[3]Buturović-PonikvarJ, PernatAM, PonikvarR, 2005. Citrate anticoagulation during plasma exchange in a patient with thrombotic thrombocytopenic purpura: short heparin-free hemodialysis helps to attenuate citrate load. Ther Apher Dial, 9(3):258-261.
[4]DaugirdasJT, 1993. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol, 4(5):1205-1213.
[5]European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association, 2002. V.1 Haemodialysis and prevention of system clotting. Nephrol Dial Transplant, 17(S7):63-71.
[6]EvenepoelP, MaesB, VanwalleghemJ, et al., 2002. Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. Am J Kidney Dis, 39(2):315-323.
[7]EvenepoelP, DejagereT, VerhammeP, et al., 2007. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis, 49(5):642-649.
[8]FaguerS, Saint-CricqM, NogierMB, et al., 2017. Heparin-free prolonged intermittent hemodialysis using calcium-free citrate dialysate in critically ill patients. Crit Care Med, 45(11):1887-1892.
[9]GuéryB, AlbertiC, ServaisA, et al., 2014. Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding. PLoS ONE, 9(5):e97187.
[10]KhwajaA, 2012. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract, 120(4):c179-c184.
[11]LinT, SongL, HuangRW, et al., 2019. Modified regional citrate anticoagulation is optimal for hemodialysis in patients at high risk of bleeding: a prospective randomized study of three anticoagulation strategies. BMC Nephrol, 20:472.
[12]MoritaY, JohnsonRW, DornRE, et al., 1961. Regional anticoagulation during hemodialysis using citrate. Am J Med Sci, 242:32-43.
[13]RichtrovaP, RulcovaK, MaresJ, et al., 2011. Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect. Artif Organs, 35(1):83-88.
[14]SchmitzM, JoannidisM, CzockD, et al., 2018. Regional citrate anticoagulation in renal replacement therapy in the intensive care station: recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI. Med Klin Intensivmed Notfmed, 113(5):377-383 (in German).
[15]SwartzRD, PortFK, 1979. Preventing hemorrhage in high-risk hemodialysis: regional versus low-dose heparin. Kidney Int, 16(4):513-518.
[16]von BrechtJH, FlaniganMJ, FreemanRM, et al., 1986. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis, 8(3):196-201.
[17]ZarbockA, KüllmarM, Kindgen-MillesD, et al., 2020. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial. JAMA, 324(16):1629-1639.
Open peer comments: Debate/Discuss/Question/Opinion
<1>